You are here

Botox

Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox

Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox

Fierce Pharma

Revance Therapeutics

Flag link:

With trial win, AbbVie cues up Botox for another cosmetic indication

With trial win, AbbVie cues up Botox for another cosmetic indication

Fierce Pharma

platysma prominence

Flag link:

Revance wants you to 'Break Up With Botox' as it goes to war with AbbVie in new anti-wrinkle market battle

Revance wants you to 'Break Up With Botox' as it goes to war with AbbVie in new anti-wrinkle market battle

Fierce Pharma

Revance Therapeutics

pharma marketing

Flag link:

Bocox for Erectile Dysfunction Announced by the Cellular Medicine Association

Bocox for Erectile Dysfunction Announced by the Cellular Medicine Association

Drugs.com

erectile dysfunction

Cellular Medicine Association

Flag link:

Goldman Sachs says this biotech working on a Botox rival drug could rally nearly 30%

Goldman Sachs says this biotech working on a Botox rival drug could rally nearly 30%

CNBC

Revance Therapeutics

Flag link:

AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved

AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved

Endpoints

Revance Therapeutics

Flag link:

Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?

Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?

Endpoints

Revance Therapeutics

Flag link:

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

BioSpace

Revance Therapeutics

glabellar lines

daxibotulinumtoxinA

Flag link:

Revance's Botox rival turned away by FDA after inspectors flagged manufacturing 'deficiencies'

Revance's Botox rival turned away by FDA after inspectors flagged manufacturing 'deficiencies'

Fierce Pharma

Revance Therapeutics

daxibotulinumtoxinA

Flag link:

AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts

AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts

Fierce Pharma

Flag link:

Can Evolus Disrupt the Botox Market?

Can Evolus Disrupt the Botox Market?

Motley Fool

Flag link:

AbbVie's Botox rolls out the red carpet for real people in new documentary-style ads

AbbVie's Botox rolls out the red carpet for real people in new documentary-style ads

Fierce Pharma

DTC advertising

Flag link:

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

Endpoints

Flag link:

AbbVie adds to the Botox war chest with a 12th FDA approval — but competition is fast approaching

AbbVie adds to the Botox war chest with a 12th FDA approval — but competition is fast approaching

Endpoints

bladder muscle overactivity

Flag link:

Aji Bio-Pharma and Revance in manufacturing deal for anti-wrinkle rival to Botox

Aji Bio-Pharma and Revance in manufacturing deal for anti-wrinkle rival to Botox

Biopharma Reporter

drug manufacturing

daxiabotulinumtoxinA

Flag link:

AbbVie's Botox wins reprieve as agency bars Evolus' Jeaveau for alleged trade-secrets theft

AbbVie's Botox wins reprieve as agency bars Evolus' Jeaveau for alleged trade-secrets theft

Fierce Pharma

Flag link:

AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

Xconomy

overactive bladder

Flag link:

AbbVie draws first blood in trade secrets war between Allergan's Botox and Evolus

AbbVie draws first blood in trade secrets war between Allergan's Botox and Evolus

Fierce Pharma

Daewoong Pharmaceuticals

Flag link:

Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

Fierce Pharma

Flag link:

Allergan unveils new Botox plant ahead of $63B AbbVie merger

Allergan unveils new Botox plant ahead of $63B AbbVie merger

Fierce Pharma

drug manufacturing

Flag link:

Pages